Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.

Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF.

Toxicol Sci. 2009 Apr;108(2):492-500. doi: 10.1093/toxsci/kfp033. Epub 2009 Feb 17.

PMID:
19223659
2.

Arsenite decreases CYP3A4 and RXRalpha in primary human hepatocytes.

Noreault TL, Kostrubsky VE, Wood SG, Nichols RC, Strom SC, Trask HW, Wrighton SA, Evans RM, Jacobs JM, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2005 Jul;33(7):993-1003. Epub 2005 Apr 15.

PMID:
15833926
3.

Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats.

Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H, Sinclair JF, Sahi J.

Toxicol Sci. 2003 Nov;76(1):220-8. Epub 2003 Aug 27.

PMID:
12944587
4.

Agree that idiosyncratic hepatotoxicity in TRO-treated patients is uncertain, but concerned about the data.

Kostrubsky VE, Rahbari R, Lodola A, Davies T.

Toxicol Sci. 2003 Feb;71(2):282; author reply 282-4. No abstract available.

PMID:
12563115
5.

Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes.

Wen YH, Sahi J, Urda E, Kulkarni S, Rose K, Zheng X, Sinclair JF, Cai H, Strom SC, Kostrubsky VE.

Drug Metab Dispos. 2002 Sep;30(9):977-84.

PMID:
12167562
6.

The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats.

Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, Altrogge D, Sinz MW.

Drug Metab Dispos. 2001 Dec;29(12):1561-6.

PMID:
11717175
7.

The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures.

Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M, Strom SC.

Drug Metab Dispos. 2000 Oct;28(10):1192-7.

PMID:
10997939
8.

Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.

Runge D, Köhler C, Kostrubsky VE, Jäger D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, Michalopoulos GK.

Biochem Biophys Res Commun. 2000 Jun 24;273(1):333-41.

PMID:
10873607
9.

Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin.

Sinclair JF, Szakacs JG, Wood SG, Kostrubsky VE, Jeffery EH, Wrighton SA, Bement WJ, Wright D, Sinclair PR.

Biochem Pharmacol. 2000 Feb 15;59(4):445-54.

PMID:
10644054
10.

Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes.

Ramachandran V, Kostrubsky VE, Komoroski BJ, Zhang S, Dorko K, Esplen JE, Strom SC, Venkataramanan R.

Drug Metab Dispos. 1999 Oct;27(10):1194-9.

PMID:
10497147
11.

The use of human hepatocyte cultures to study the induction of cytochrome P-450.

Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, Strom SC.

Drug Metab Dispos. 1999 Aug;27(8):887-94.

PMID:
10421615
12.

Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.

Jacobs JM, Nichols CE, Andrew AS, Marek DE, Wood SG, Sinclair PR, Wrighton SA, Kostrubsky VE, Sinclair JF.

Toxicol Appl Pharmacol. 1999 May 15;157(1):51-9.

PMID:
10329507
13.

Epidermal growth factor- and hepatocyte growth factor-receptor activity in serum-free cultures of human hepatocytes.

Runge DM, Runge D, Dorko K, Pisarov LA, Leckel K, Kostrubsky VE, Thomas D, Strom SC, Michalopoulos GK.

J Hepatol. 1999 Feb;30(2):265-74.

PMID:
10068107
14.

Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes.

Kostrubsky VE, Lewis LD, Strom SC, Wood SG, Schuetz EG, Schuetz JD, Sinclair PR, Wrighton SA, Sinclair JF.

Arch Biochem Biophys. 1998 Jul 15;355(2):131-6.

PMID:
9675018
15.

Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity.

Kostrubsky VE, Szakacs JG, Jeffery EH, Wood SG, Bement WJ, Wrighton SA, Sinclair PR, Sinclair JF.

Toxicol Appl Pharmacol. 1997 Apr;143(2):315-23.

PMID:
9144448
16.

Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone.

Kostrubsky VE, Lewis LD, Wood SG, Sinclair PR, Wrighton SA, Sinclair JF.

Toxicol Appl Pharmacol. 1997 Jan;142(1):79-86.

PMID:
9007036
17.

Protection of ethanol-mediated acetaminophen hepatotoxicity by triacetyloleandomycin, a specific inhibitor of CYP3A.

Kostrubsky VE, Szakacs JG, Jeffery EH, Woods SG, Bement WJ, Wrighton SA, Sinclair PR, Sinclair JF.

Ann Clin Lab Sci. 1997 Jan-Feb;27(1):57-62.

PMID:
8997458
18.

Acute hepatotoxicity of acetaminophen in rats treated with ethanol plus isopentanol.

Kostrubsky VE, Wood SG, Bush MD, Szakacs J, Bement WJ, Sinclair PR, Jeffery EH, Sinclair JF.

Biochem Pharmacol. 1995 Nov 27;50(11):1743-8.

PMID:
8615851
19.

Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes.

Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF.

Arch Biochem Biophys. 1995 Oct 1;322(2):516-20.

PMID:
7574728

Supplemental Content

Loading ...
Support Center